0
0
8/1/23 at 9:55pm
Organization
Forbes
Author
Joshua Cohen
44 words
0
Comments
As CMS expands coverage of Leqembi it’s unclear how patient registries will work, how comprehensive scan coverage will be, and whether local carriers have any discretion.
You are the first to view
https://www.forbes.com/sites/joshuacohen/2023/08/01/as-medicare-broadens-coverage-of-alzheimers-disease-drug-leqembi-details-emerge-regarding-what-access-entails/
Create an account
or login to join the discussion